Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
NEW YORK – Layer Health is developing its large language model (LLM)-based data abstraction platform as a tool to help doctors make individualized treatment decisions for patients using the totality ...
NEW YORK – Cargo Therapeutics this week said it is suspending development of its CD19/CD20/CD21 tri-specific autologous CAR T-cell therapy CRG-023 in B-cell malignancies and reducing its workforce by ...
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.
By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for ...
The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.
Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...
NEW YORK – Servier has signed a global licensing agreement with Black Diamond Therapeutics to develop and commercialize BDTX-4933 for treating RAF- and RAS-mutant solid tumors, including non-small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback